(MENAFN) After a second trial failure delivered a serious blow to the French healthcare company's growth prospects, Sanofi has halted further work on amcenestrant, a therapy that had previously been thought to have significant commercial promise in the treatment of breast cancer.
The action hurt shares and increased pressure on Sanofi to expand its drug candidate pipeline as it grows more reliant on its multi-billion-dollar best seller, the rapidly expanding eczema and asthma medication Dupixent.
Sanofi is likewise far behind the competition in the creation of COVID-19 vaccines.
An independent monitoring panel found no indications of efficacy in the AMEERA-5 trial, which tested amcenestrant on women with newly diagnosed advanced breast cancer.
The shares had a 5.7 percent decline at the closing, which was the second-largest decline on the CAC40 French Blue Chip Index.
Separately, the plaintiff in the initial complaint involving the heartburn medication Zantac, which has also recently affected Sanofi's shares, decided to dismiss his case on Tuesday.
A number of businesses, including Sanofi, sold Zantac until US regulators decided to remove it from the market in 2020.
MENAFN19082022000045011137ID1104724339
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.